Sign in
Taking people in United StatesNo phase

Observes real-world use of KarXT in adults with schizophrenia

Studies how adults with schizophrenia fare on KarXT in routine care.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Anaheim, Apple Valley, Atlanta, Austell, Austin, Bloomfield Township, Bonita Springs, Bryant, Buffalo, Cary, Charlotte, Chino, Cordova, Crystal Lake, Dallas, Detroit, Duluth, Fort Worth, Franklin, Hagerstown, Hartford, Hialeah, Homestead, Houston, Irving, Kendall, La Palma, Las Vegas, Lincoln, Marietta, Mason, McKinney, Miami, Mission Viejo, Monsey, Nashville, Oceanside, Oklahoma City, Orange City, Orland Park, Orlando, Petersburg, Philadelphia, Redlands, Richmond, Rochester, San Antonio, San Diego, Seal Beach, Stafford, Stanford, State College, Tulsa, Warrenville, White Plains, Wilmington, Worcester, and Wyomissing, United StatesSee the 68 sites
Trial code
Registry title
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Status
Recruiting
People taking part
1,500 people, planned
Started
26 Feb 2026
Expected to end
20 Jun 2028
Type of study
Observational
Treatments tested
  • Xanomeline and trospium chloride (KarXT)
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with schizophrenia who have started, or are about to start, KarXT (xanomeline and trospium chloride) in place of their current antipsychotic medicine.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Schizophrenia, confirmed by the treating clinician or by the doctor's decision to treat with KarXT.
Earlier treatment
Must be on a stable antipsychotic regimen for at least 30 days with a plan to switch to KarXT, or be less than 16 weeks into KarXT with the intent to stop the earlier antipsychotic. People who stopped KarXT earlier cannot join.

Main reasons for not taking part

  • Earlier use of KarXT that was stopped before the start of the study
  • Joined an interventional study in the last 30 days, or plans to join one
  • Known allergy to xanomeline or trospium chloride
  • History or high risk of urinary retention or gastric retention, moderate or severe liver impairment, or narrow-angle glaucoma
  • Pregnant, planning pregnancy, or breastfeeding

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participants (or caregiver/legal guardian) must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines
  • Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up
  • Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride (KarXT) for schizophrenia made prior to and independently of participation in this study. Current Antipsychotic Treatment: Participant must fall into one of the categories below:; Be within <16 weeks of initiating treatment with KarXT with intent to discontinue prior antipsychotic treatment(s) OR; On a stable regimen (dose and frequency consistent with the drug label and/or at a stable dose based on the judgement of the Investigator for at least 30 days prior to screening) of treatment with 1 or more antipsychotics with plan to discontinue and switch to treatment with KarXT from a prior antipsychotic treatments(s). NOTE: The decision to switch for reasons of safety, tolerability, and/or efficacy will be made independently by the treating clinician and/or the patient and is not dictated by the study. Participants can be enrolled during tapering/discontinuing process from prior antipsychotic treatment(s). Individuals who are not currently receiving treatment for schizophrenia are not eligible for the study. Any antipsychotic treatments must be recorded as concomitant medications
  • Concomitant psychiatric medications (eg, antidepressants, mood stabilizers, anxiolytics) are permitted and are recommended to remain at a stable dose during the study period

Who cannot take part

  • Prior use of KarXT that has been discontinued for any reason prior to Baseline
  • Known hypersensitivity to xanomeline or trospium chloride, or history or high risk of urinary retention, gastric retention, moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, or narrow-angle glaucoma
  • In the opinion of the treating clinician, unstable psychiatric or medical conditions that would prevent the participant from safely switching to KarXT. Hospitalized individuals who have been switched to KarXT or are switching treatment to KarXT are permitted to be enrolled at discharge if they are < 16 weeks from initiation of KarXT
  • Participation in an interventional study within the last 30 days or plans to participate in an interventional study at the time of eligibility or baseline through the study period
  • Participants who are pregnant, planning to become pregnant, or breastfeeding

Where in United States

  • Anaheim, CaliforniaHospital not named in the registryContact: Site 0003Not yet recruiting
  • Pamoja Advanced Nursing PracticeAnaheim, United StatesContact: Fines Shaw, Site 0047Taking people
  • Apple Valley, MinnesotaHospital not named in the registryContact: Site 0034Not yet recruiting
  • Emory UniversityAtlanta, United StatesContact: Robert Cotes, Site 0025Taking people
  • Avant PsychiatryAustell, United StatesContact: Okah Anyokwu, Site 0049Taking people
  • Austin, TexasHospital not named in the registryContact: Site 0016Not yet recruiting
  • Bloomfield Township, MichiganHospital not named in the registryContact: Site 0014Not yet recruiting
  • Envision Trials LLCBonita Springs, United StatesContact: Daniel Mandri, Site 0005Taking people
  • SanRo Clinical Research GroupBryant, United StatesContact: Robert Wooten, Site 0009Taking people
  • Buffalo, New YorkHospital not named in the registryContact: Site 0037Not yet recruiting
  • Magnolia Clinical Research LLCCary, United StatesContact: Michelle Maust, Site 0042Taking people
  • Charlotte, North CarolinaHospital not named in the registryContact: Site 0057Not yet recruiting
  • Inland Psychiatric Medical Group (IPMG)-ChinoChino, United StatesContact: Nandita Puchakayala, Site 0039Taking people
  • Cordova, TennesseeHospital not named in the registryContact: Site 0051Not yet recruiting
  • Crystal Lake, IllinoisHospital not named in the registryContact: Site 0046Not yet recruiting
  • Dallas, TexasHospital not named in the registryContact: Site 0050Not yet recruiting
  • Detroit, MichiganHospital not named in the registryContact: Site 0036Not yet recruiting
  • Duluth, MinnesotaHospital not named in the registryContact: Site 0054Not yet recruiting
  • SCLA Management- Psymed SolutionsFort Worth, United StatesContact: Satish Narayan, Site 0021Taking people
  • Psychiatric Consultants, PCFranklin, United StatesContact: James Hart, Site 0002Taking people
  • Hagerstown, MarylandHospital not named in the registryContact: Site 0067Not yet recruiting
  • Hartford, ConnecticutHospital not named in the registryContact: Site 0056Not yet recruiting
  • Hartford, ConnecticutHospital not named in the registryContact: Site 0059Not yet recruiting
  • Galiz ResearchHialeah, United StatesContact: Jose Gamez, Site 0019Taking people
  • Homestead, FloridaHospital not named in the registryContact: Site 0030Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Site 0022Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Site 0026Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Site 0033Not yet recruiting
  • Houston, TexasHospital not named in the registryContact: Site 0010Not yet recruiting
  • Pioneer Research Solutions, Inc.Houston, United StatesContact: Ateka Zaki, Site 0024Taking people
  • Irving, TexasHospital not named in the registryContact: Site 0017Not yet recruiting
  • New Access Research & Medical Services Inc - KendallKendall, United StatesContact: Ana Maria Tous, Site 0029Taking people
  • La Palma, CaliforniaHospital not named in the registryContact: Site 0012Not yet recruiting
  • Las Vegas, NevadaHospital not named in the registryContact: Site 0055Not yet recruiting
  • Alivation Research, LLCLincoln, United StatesContact: Walter Duffy, Site 0041Taking people
  • Marietta, GeorgiaHospital not named in the registryContact: Site 0044Not yet recruiting
  • Mason, OhioHospital not named in the registryContact: Site 0031Not yet recruiting
  • McKinney, TexasHospital not named in the registryContact: Site 0013Not yet recruiting
  • Miami, FloridaHospital not named in the registryContact: Site 0007Not yet recruiting
  • Miami, FloridaHospital not named in the registryContact: Site 0032Not yet recruiting
  • Banyan Behavioal Care Program - CSUMiami, United StatesContact: Moraima Trujillo, Site 0011Taking people
  • BioResearch Partner - MiamiMiami, United StatesContact: Fenton Lebon, Site 0006Taking people
  • Mission Viejo, CaliforniaHospital not named in the registryContact: Site 0062Not yet recruiting
  • Monsey, New YorkHospital not named in the registryContact: Site 0004Not yet recruiting
  • Nashville, TennesseeHospital not named in the registryContact: Site 0066Not yet recruiting
  • Oceanside, CaliforniaHospital not named in the registryContact: Site 0043Not yet recruiting
  • The Rivus Wellness & Research InstituteOklahoma City, United StatesContact: Marvin Peyton, Site 0027Taking people
  • Medical Research of Central FloridaOrange City, United StatesContact: Adly Thebaud, Site 0023Taking people
  • Orland Park, IllinoisHospital not named in the registryContact: Site 0061Not yet recruiting
  • Orlando, FloridaHospital not named in the registryContact: Site 0040Not yet recruiting
  • Petersburg, VirginiaHospital not named in the registryContact: Site 0045Not yet recruiting
  • Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, United StatesContact: Christian Kohler, Site 0015Taking people
  • Redlands, CaliforniaHospital not named in the registryContact: Site 0068Not yet recruiting
  • Perceptive Pharma ResearchRichmond, United StatesContact: Adeeb Masood, Site 0008Taking people
  • Rochester, New YorkHospital not named in the registryContact: Site 0038Not yet recruiting
  • UT Health San Antonio - Behavioral Health and Wellness CenterSan Antonio, United StatesContact: Mady Stovall, Site 0035Taking people
  • San Diego, CaliforniaHospital not named in the registryContact: Site 0060Not yet recruiting
  • Seal Beach, CaliforniaHospital not named in the registryContact: Site 0063Not yet recruiting
  • R & H Clinical Research-3727 Greenbriar DrStafford, United StatesContact: Syed Zaidi, Site 0018Taking people
  • Stanford, CaliforniaHospital not named in the registryContact: Site 0028Not yet recruiting
  • State College, PennsylvaniaHospital not named in the registryContact: Site 0053Not yet recruiting
  • Tulsa, OklahomaHospital not named in the registryContact: Site 0052Not yet recruiting
  • Amr Conventions Research - IllinoisWarrenville, United StatesContact: Sandeep Gaonkar, Site 0048Taking people
  • Phillips Medical Services PLLCWhite Plains, United StatesContact: Parinda Parikh, Site 0020Taking people
  • PPD Virtual - PPD - USWilmington, United StatesContact: Ghazaleh Bahrami, Site 0001Taking people
  • Worcester, MassachusettsHospital not named in the registryContact: Site 0065Not yet recruiting
  • Worcester, MassachusettsHospital not named in the registryContact: Site 0058Not yet recruiting
  • Wyomissing, PennsylvaniaHospital not named in the registryContact: Site 0064Not yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

The group in the trial

  • Group 1

    Participants diagnosed with schizophrenia receiving xanomeline and trospium chloride (KarXT)

    Treatment: Xanomeline and trospium chloride (KarXT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effectiveness and Adverse-effect Switch Evaluation
Plain-language title
Observes real-world use of KarXT in adults with schizophreniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 November 2026